Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
RESEARCH TOOLSreports
Ultragenyx Pharmaceutical (RARE) Stock Price & Analysis
580 Followers
RARE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$31.52 - $54.98
Previous Close$46.69
Volume543.70K
Average Volume (3M)764.08K
Market Cap
$3.84B
Enterprise Value$3.40B
Total Cash (Recent Filing)$442.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-5.6
Beta0.90
Next Earnings
May 02, 2024EPS Estimate
-$1.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.33
Shares Outstanding82,335,687
10 Day Avg. Volume678,275
30 Day Avg. Volume764,081
Standard Deviation0.14
R-Squared0.06
Alpha-0.00145
Financial Highlights & Ratios
Price to Book (P/B)59.38
Price to Sales (P/S)37.20
Price to Cash Flow (P/CF)-11.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.77
Enterprise Value/Gross Profit9.36
Enterprise Value/Ebitda-6.83
Forecast
1Y Price Target
$89.87Price Target Upside92.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Ultragenyx Pharmaceutical News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
RARE FAQ
What was Ultragenyx Pharmaceutical’s price range in the past 12 months?
Ultragenyx Pharmaceutical lowest stock price was $31.52 and its highest was $54.98 in the past 12 months.
What is Ultragenyx Pharmaceutical’s market cap?
Currently, no data Available
When is Ultragenyx Pharmaceutical’s upcoming earnings report date?
Ultragenyx Pharmaceutical’s upcoming earnings report date is May 02, 2024 which is in 16 days.
How were Ultragenyx Pharmaceutical’s earnings last quarter?
Ultragenyx Pharmaceutical released its earnings results on Feb 15, 2024. The company reported -$1.52 earnings per share for the quarter, beating the consensus estimate of -$1.707 by $0.187.
Is Ultragenyx Pharmaceutical overvalued?
According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Undervalued.
Does Ultragenyx Pharmaceutical pay dividends?
Ultragenyx Pharmaceutical does not currently pay dividends.
What is Ultragenyx Pharmaceutical’s EPS estimate?
Ultragenyx Pharmaceutical’s EPS estimate is -$1.76.
How many shares outstanding does Ultragenyx Pharmaceutical have?
Ultragenyx Pharmaceutical has 82,335,686 shares outstanding.
What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?
Ultragenyx Pharmaceutical reported an EPS of -$1.52 in its last earnings report, beating expectations of -$1.707. Following the earnings report the stock price went up 5.75%.
Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?
Among the largest hedge funds holding Ultragenyx Pharmaceutical’s share is Sands Capital Management LLC. It holds Ultragenyx Pharmaceutical’s shares valued at 197M.
---
Ultragenyx Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$89.87 (92.48% Upside)
$89.87 (92.48% Upside)
Blogger Sentiment
Neutral
RARE Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 4.9%
Last 30 Days ▲ 4.6%
Last 30 Days ▲ 4.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.97%
12-Months-Change
Fundamentals
Return on Equity
-193.23%
Trailing 12-Months
Asset Growth
-3.52%
Trailing 12-Months
Company Description
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.
---
RARE Earnings Call
Q4 2024
0:00 / 0:00
---
RARE Stock 12 Months Forecast
Average Price Target
$89.87
▲(92.48% Upside)
Technical Analysis
Best Analysts Covering RARE
1 Year
1 Year Success Rate
10/16 ratings generated profit
1 Year Average Return
+55.84%
reiterated a buy rating 2 months ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +55.84% per trade.
---